IL-5[Biotinylated]:IL-5Rα Inhibitor Screening ELISA Kit
Background/背景
Interleukin (IL)-5 is produced and secreted by T cells and mast cellsa critical,and is the important regulator of eosinophils and a therapeutic target for asthma. The pharmaceutical inhibition of IL-5 has been shown to reduce eosinophil counts and ameliorate asthmatic symptoms in studies on animal models of allergy as well as in human clinical trials. There are currently three commercially available IL-5 inhibitors in the United States. These include reslizumab (trade name Cinqair), benralizumab (trade name Fasenra), and mepolizumab (trade name Nucala). All three medications have been approved by the FDA for the treatment of severe eosinophilic asthma.
Assay Principles/原理
This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new IL-5 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human IL-5 to immobilized human IL-5 R alpha in a functional ELISA assay, and employs a simple colorimetric sandwich ELISA platform.
Your experiment will include 4 simple steps:
a) Coat the plate with human IL-5 R alpha.
b) Add your molecule of interest to the tests.
c) Add human IL-5-Biotin to bind the coated human IL-5 R alpha.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
e) Finally, the ability of your compound to inhibit IL-5: IL-5 R alpha Rbinding will be determined by comparing OD readings among different experimental groups.
Application/应用
This kit is developed for screening for inhibitors of human IL-5Rα binding to human IL-5.
It is for research use only.
Reconstitution/重构方法
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage/存储
The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
关键字: IL-5 ELISA Kit;IL-5试剂盒;IL-5 ELISA试剂盒;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。